Novel recombinant glycosylphosphatidylinositol (GPI)-anchored ADAMTS13 and variants for assessment of anti-ADAMTS13 autoantibodies in patients with thrombotic thrombocytopenic purpura

Thrombosis and Haemostasis

Volumn 106, Issue 5, 2011, Pages 947-958

  Li, Dengju ^a   Xiao, Juan ^a   Paessler, Michele ^a   Zheng, X Long ^a  

^a HOSPITAL OF THE UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

And autoantibody; Diagnostic test; Thrombotic microangiopathies; Von willebrand factor cleaving protease

Indexed keywords

AUTOANTIBODY; EPITOPE; GLYCOSYLPHOSPHATIDYLINOSITOL ANCHORED PROTEIN; IMMUNOGLOBULIN G ANTIBODY; RECOMBINANT PROTEIN; UNCLASSIFIED DRUG; VON WILLEBRAND FACTOR CLEAVING PROTEINASE; VON WILLEBRAND FACTOR CLEAVING PROTEINASE ANTIBODY;

ADULT; AGED; ANIMAL CELL; ANTIBODY AFFINITY; ANTIBODY BLOOD LEVEL; ANTIBODY DETECTION; ANTIGEN ANTIBODY COMPLEX; ANTIGEN BINDING; ARTICLE; BLOOD DONOR; CARBOXY TERMINAL SEQUENCE; CELL ASSAY; CELL MEMBRANE; CLINICAL ARTICLE; CONTROLLED STUDY; ENZYME KINETICS; FEMALE; HUMAN; HUMAN CELL; MALE; MICROTITER PLATE ASSAY; NONHUMAN; PRIORITY JOURNAL; PROTEIN AGGREGATION; PROTEIN BINDING; PROTEIN DOMAIN; PROTEIN EXPRESSION; THROMBOCYTE ADHESION; THROMBOTIC THROMBOCYTOPENIC PURPURA;

ADAM PROTEINS; ADULT; AGED; ANIMALS; AUTOANTIBODIES; BIOLOGICAL ASSAY; BIOLOGICAL MARKERS; CASE-CONTROL STUDIES; CELL MEMBRANE; CHO CELLS; CRICETINAE; CRICETULUS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FLOW CYTOMETRY; GLYCOSYLPHOSPHATIDYLINOSITOLS; HUMANS; MALE; MICROSCOPY, FLUORESCENCE; MIDDLE AGED; PHILADELPHIA; PREDICTIVE VALUE OF TESTS; PURPURA, THROMBOTIC THROMBOCYTOPENIC; RECOMBINANT PROTEINS; SENSITIVITY AND SPECIFICITY; TIME FACTORS; TRANSFECTION; TREATMENT OUTCOME; YOUNG ADULT;

EID: 80155138041     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/TH11-05-0337     Document Type: Article

References (39)

1. Tsai HM. Current concepts in thrombotic thrombocytopenic purpura. Annu Rev Med 2006; 57: 419-436.
2. Levy GG, Nichols WC, Lian EC, et al. Mutations in a member of the ADAMTS gene family cause thrombotic thrombocytopenic purpura. Nature 2001; 413: 488-494.
3. Klaus C, Plaimauer B, Studt JD, et al. Epitope mapping of ADAMTS13 autoantibodies in acquired thrombotic thrombocytopenic purpura. Blood 2004; 103: 4514-4519.
4. Tsai HM, Lian EC. Antibodies to von Willebrand factor-cleaving protease in acute thrombotic thrombocytopenic purpura. N Engl J Med 1998; 339: 1585-1594.
5. Esplin MS, Branch DW. Diagnosis and management of thrombotic microangiopathies during pregnancy. Clin Obstet Gynecol 1999; 42: 360-367.
6. Elliott MA, Nichols WL, Jr., Plumhoff EA, et al. Posttransplantation thrombotic thrombocytopenic purpura: a single-center experience and a contemporary review. Mayo Clin Proc 2003; 78: 421-430.
7. Bar Meir E, Amital H, Levy Y, et al. Mycoplasma-pneumoniae-induced thrombotic thrombocytopenic purpura. Acta Haematol 2000; 103: 112-115.
8. Fontana S, Gerritsen HE, Kremer Hovinga J, et al. Microangiopathic haemolytic anaemia in metastasizing malignant tumours is not associated with a severe deficiency of the von Willebrand factor-cleaving protease. Br J Haematol 2001; 113: 100-102.
9. Bennett CL, Kim B, Zakarija A, et al. Two mechanistic pathways for thienopyridine-associated thrombotic thrombocytopenic purpura: a report from the SERFTTP Research Group and the RADAR Project. J Am Coll Cardiol 2007; 50: 1138-1143.
10. Tsai HM. Is severe deficiency of ADAMTS-13 specific for thrombotic thrombocytopenic purpura? Yes. J Thromb Haemost 2003; 1: 625-631.
11. Veyradier A, Obert B, Houllier A, et al. Specific von Willebrand factor-cleaving protease in thrombotic microangiopathies: a study of 111 cases. Blood 2001; 98: 1765-1772.
12. Zheng XL. ADAMTS13 testing: why bother? Blood 2010; 115: 1475-1476.
13. Coppo P, Wolf M, Veyradier A, et al. Prognostic value of inhibitory anti-ADAMTS13 antibodies in adult-acquired thrombotic thrombocytopenic purpura. Br J Haematol 2006; 132: 66-74.
14. Hovinga JA, Vesely SK, Terrell DR, et al. Survival and relapse in patients with thrombotic thrombocytopenic purpura. Blood 2010; 115: 1500-1511.
15. Zheng XL, Richard KM, Goodnough LT, et al. Effect of plasma exchange on plasma ADAMTS13 metalloprotease activity, inhibitor level, and clinical outcome in patients with idiopathic and non-idiopathic thrombotic thrombocytopenic purpura. Blood 2004; 103: 4043-4049.
16. Peyvandi F, Lavoretano S, Palla R, et al. ADAMTS13 and anti-ADAMTS13 antibodies as markers for recurrence of acquired thrombotic thrombocytopenic purpura during remission. Haematologica 2008; 93: 232-239.
17. Cataland SR, Jin M, Lin S, et al. Cyclosporin and plasma exchange in thrombotic thrombocytopenic purpura: long-term follow-up with serial analysis of ADAMTS13 activity. Br J Haematol 2007; 139: 486-493.
18. Zheng XL, Pallera AM, Goodnough LT, et al. Remission of chronic thrombotic thrombocytopenic purpura after treatment with cyclophosphamide and rituximab. Ann Intern Med 2003; 138: 105-108.
19. Fakhouri F, Teixeira L, Delarue R, et al. Responsiveness of thrombotic thrombocytopenic purpura to rituximab and cyclophosphamide. Ann Intern Med 2004; 140: 314-315.
20. Bresin E, Gastoldi S, Daina E, et al. Rituximab as pre-emptive treatment in patients with thrombotic thrombocytopenic purpura and evidence of anti-ADAMTS13 autoantibodies. Thromb Haemost 2009; 101: 233-238.
21. Scully M, Cohen H, Cavenagh J, et al. Remission in acute refractory and relapsing thrombotic thrombocytopenic purpura following rituximab is associated with a reduction in IgG antibodies to ADAMTS-13. Br J Haematol 2007; 136: 451-461.
22. Furlan M, Robles R, Solenthaler M, et al. Acquired deficiency of von Willebrand factor-cleaving protease in a patient with thrombotic thrombocytopenic purpura. Blood 1998; 91: 2839-2846.
23. Shelat SG, Smith AG, Ai J, et al. Inhibitory autoantibodies against ADAMTS-13 in patients with thrombotic thrombocytopenic purpura bind ADAMTS-13 protease and may accelerate its clearance in vivo. J Thromb Haemost 2006; 4: 1707-1717.
24. Palla R, Valsecchi C, Bajetta M, et al. Evaluation of assay methods to measure plasma ADAMTS13 activity in thrombotic microangiopathies. Thromb Haemost 2011; 105: 381-385.
25. Ferrari S, Scheiflinger F, Rieger M, et al. Prognostic value of anti-ADAMTS 13 antibody features (Ig isotype, titer, and inhibitory effect) in a cohort of 35 adult French patients undergoing a first episode of thrombotic microangiopathy with undetectable ADAMTS 13 activity. Blood 2007; 109: 2815-2822.
26. Ferrari S, Mudde GC, Rieger M, et al. IgG subclass distribution of anti-ADAMTS13 antibodies in patients with acquired thrombotic thrombocytopenic purpura. J Thromb Haemost 2009; 7: 1703-1710.
27. Zheng XL, Wu HM, Shang D, et al. Multiple domains of ADAMTS13 are targeted by autoantibodies against ADAMTS13 in patients with acquired idiopathic thrombotic thrombocytopenic purpura. Haematologica 2010; 95: 1555-1562.
28. Vesely SK, George JN, Lammle B, et al. ADAMTS13 activity in thrombotic thrombocytopenic purpura-hemolytic uremic syndrome: relation to presenting features and clinical outcomes in a prospective cohort of 142 patients. Blood 2003; 102: 60-68.
29. Han Y, Xiao J, Falls E, et al. A shear-based assay for assessing plasma ADAMTS13 activity and inhibitors in patients with thrombotic thrombocytopenic purpura. Transfusion 2011; 51: 1580-1591.
30. Tsai HM, Raoufi M, Zhou W, et al. ADAMTS13-binding IgG are present in patients with thrombotic thrombocytopenic purpura. Thromb Haemost 2006; 95: 886-892.
31. Rieger M, Mannucci PM, Kremer Hovinga JA, et al. ADAMTS13 autoantibodies in patients with thrombotic microangiopathies and other immunomediated diseases. Blood 2005; 106: 1262-1267.
32. Lublin DM, Atkinson JP. Decay-accelerating factor: biochemistry, molecular biology, and function. Annu Rev Immunol 1989; 7: 35-58.
33. Ai J, Smith P, Wang S, et al. The proximal carboxyl-terminal domains of ADAMTS13 determine substrate specificity and are all required for cleavage of von Willebrand factor. J Biol Chem 2005; 280: 29428-29434.
34. Zheng XL, Nishio K, Majerus EM, et al. Cleavage of von Willebrand factor requires the spacer domain of the metalloprotease ADAMTS13. J Biol Chem 2003; 278: 30136-30141.
35. Kokame K, Nobe Y, Kokubo Y, et al. FRETS-VWF73, a first fluorogenic substrate for ADAMTS13 assay. Br J Haematol 2005; 129: 93-100.
36. Luken BM, Turenhout EA, Hulstein JJ, et al. The spacer domain of ADAMTS13 contains a major binding site for antibodies in patients with thrombotic thrombocytopenic purpura. Thromb Haemost 2005; 93: 267-274.
37. Muniz M, Riezman H. Intracellular transport of GPI-anchored proteins. EMBO J 2000; 19: 10-15.
38. Allford SL, Hunt BJ, Rose P, et al. Guidelines on the diagnosis and management of the thrombotic microangiopathic haemolytic anaemias. Br J Haematol 2003; 120: 556-573.
39. Fakhouri F, Vernant JP, Veyradier A, et al. Efficiency of curative and prophylactic treatment with rituximab in ADAMTS13 deficient-thrombotic thrombocytopenic purpura: a study of 11 cases. Blood 2005; 106: 1932-1937.